Wolverine Stack vs Glow Protocol

If you've spent any time in peptide communities on TikTok, Reddit, or biohacking forums, you've almost certainly encountered both of these names. The Wolverine Stack and the Glow Protocol are two of the most widely discussed healing peptide combinations in community use — and understanding what distinguishes them, and who each one is actually for, helps cut through a lot of noise.

The short version: the Wolverine Stack is BPC-157 + TB-500, built around injury recovery and tissue repair. The Glow Protocol is the same two compounds with GHK-Cu added, extending the focus to include skin quality, collagen synthesis, and anti-aging outcomes. The Glow Protocol is essentially a superset of the Wolverine Stack — not a different approach, but an expanded one.

Where the Names Come From

Neither "Wolverine Stack" nor "Glow Protocol" is a clinical or scientific designation. Both names originated in online biohacking and peptide communities, likely on forums like Reddit's r/Peptides and r/PEDs before migrating to TikTok where they gained significantly wider reach. The Wolverine name is a reference to the Marvel character's near-instantaneous regenerative healing ability — it's aspirational branding that communicates the stack's purpose instantly. The Glow Protocol name captures the skin and anti-aging focus that differentiates it from the recovery-first Wolverine Stack.

It's worth being clear: these are community naming conventions, not standardised formulations. Different sources describe slightly different compound choices and dose ranges under these names. What is described here reflects the most commonly discussed versions across major peptide communities.

The Wolverine Stack — BPC-157 + TB-500

BPC-157 — The Anchor Compound

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a gastric juice protein sequence. Its preclinical research profile is extensive — among the most studied healing peptides — with documented effects on tendon and ligament repair, angiogenesis (new blood vessel formation), gut lining integrity, and neurological tissue repair.

Mechanistically, BPC-157 appears to work primarily through upregulation of growth factor expression (VEGF, EGF), modulation of nitric oxide synthesis, and direct effects on fibroblast proliferation. Its half-life is short — approximately 30 minutes — which means daily dosing at the injury site or systemically is the common approach. The short half-life also means there is no meaningful accumulation between doses; each injection produces a discrete pharmacological window rather than building to a sustained steady-state level.

In community use, BPC-157 is most commonly injected subcutaneously near the injury site for localised issues (tendon, joint, gut) or systemically for general recovery support. Nasal administration is also practised for systemic distribution and potential neurological effects, though injection is the more common route.

TB-500 — The Systemic Amplifier

TB-500 (Thymosin Beta-4, or the synthetic fragment thereof) complements BPC-157 through a different but complementary mechanism. Where BPC-157 acts primarily through local tissue signalling and growth factor modulation, TB-500 works more systemically — it regulates actin polymerisation, promotes cell migration, reduces inflammation at a systemic level, and supports new blood vessel and muscle fibre formation.

TB-500 has a longer half-life than BPC-157 (approximately 2 hours, with effects likely persisting longer through downstream signalling). Community protocols typically involve less frequent dosing — often twice weekly rather than daily — reflecting the compound's longer activity window and the typical observation that less frequent, higher doses are more practical for the SubQ IM administration most often used.

The synergy rationale for running both together is mechanistic: BPC-157 provides dense local tissue signalling and growth factor upregulation, while TB-500 provides broader systemic anti-inflammatory and regenerative signalling. Many users report that the combination produces outcomes not fully explained by either compound alone — though this remains community observation rather than controlled data.

The Glow Protocol — BPC-157 + TB-500 + GHK-Cu

GHK-Cu — The Glow Addition

GHK-Cu is a naturally occurring copper-binding tripeptide (Glycine-Histidine-Lysine) that is endogenous to human plasma. Plasma concentrations of GHK-Cu naturally decline with age, which forms the basis of its appeal in anti-aging and longevity contexts. Its documented mechanisms include stimulation of collagen and glycosaminoglycan synthesis, activation of wound repair genes, antioxidant activity, and modulation of over 4,000 genes involved in tissue remodelling according to gene expression studies.

For skin specifically, GHK-Cu has the most substantial research base of any cosmetic peptide — including significant peer-reviewed literature on topical application. Injectable GHK-Cu is used in community protocols primarily for systemic effects (collagen throughout the body, wound healing, hair follicle support) alongside or instead of topical application.

GHK-Cu has a very short half-life (~4 hours) and a notably mild side effect profile. The primary reported effects are mild localised skin reactions at injection sites and, in some users, a period of mild fatigue when starting the protocol. Its addition to the Wolverine Stack does not meaningfully change the side effect profile of the overall combination.

Side-by-Side Comparison

Week-by-Week Timeline — What to Expect

The following reflects commonly reported timelines in community use. Individual responses vary substantially based on injury type, protocol consistency, baseline health, and individual pharmacological response.

Can You Combine Them? The Full Three-Compound Stack

Since the Glow Protocol is the Wolverine Stack with GHK-Cu added, running all three compounds simultaneously is the default implementation of the Glow Protocol rather than a novel combination. The compounds do not have known negative interactions with each other — their mechanisms are complementary and operate through distinct receptor systems and signalling pathways.

The practical considerations when running all three are logistical rather than pharmacological:

• Three reconstituted vials require separate storage and tracking. Each has a different reconstituted stability window (typically 30-60 days refrigerated for peptides reconstituted in bacteriostatic water).
• Injection frequency increases — typically 2-3 SubQ injections daily depending on protocol structure. Rotating injection sites across the three compounds reduces site-specific reactions.
• Cost scales linearly with compound count — running three compounds is approximately 1.5x the cost of the two-compound Wolverine Stack depending on sourcing.

Tracking a Multi-Compound Stack

One of the underappreciated challenges of running either of these stacks — and particularly the three-compound Glow Protocol — is that each compound has a different half-life and therefore a different saturation timeline. This matters for interpreting when effects are expected and for understanding which compound is contributing to which observed outcome.

BPC-157 has a half-life of approximately 30 minutes. It reaches steady-state concentration quickly but also clears quickly — meaning a missed dose has an immediate impact on plasma levels. TB-500's effective activity window is longer (~2 hours half-life), producing more sustained systemic exposure per dose. GHK-Cu at ~4 hours half-life sits between the two in terms of accumulation pattern, but given its primary mechanism involves gene expression modulation rather than receptor occupancy, its effects are less immediately dependent on plasma levels than classical pharmacokinetics would suggest.

Running a multi-compound stack without systematic dose logging makes it genuinely difficult to attribute effects — or side effects, or lack of progress — to specific compounds. When all three are performing as expected, this isn't a problem. When something isn't working as expected, the attribution challenge becomes significant. Tracking each compound's dosing independently, alongside subjective markers (recovery feel, soreness, skin quality), allows a far more interpretable dataset than memory-based retrospective assessment.

This is also why per-compound level curves matter even for short-half-life compounds like BPC-157 — not because the pharmacokinetic model is as informative as it is for long-acting compounds like testosterone, but because the dose-timing correlation with subjective markers provides signal that's otherwise lost.

Frequently Asked Questions